Lipids, Lipodystrophy, and Obesity:
Metabolic Issues in HIV

Metabolic Issues in HIV

This activity is jointly provided by the Annenberg Center for Health Sciences at Eisenhower, the American Academy of HIV Medicine, in collaboration with Postgraduate Institute for Medicine.

This activity is supported by an independent educational grant from Gilead Sciences.

Target Audience
This activity has been designed to meet the educational needs of physicians, physician assistants, nurse practitioners, and pharmacists; other healthcare providers, such as nurses, nutritionists, social workers, and case managers are also encouraged to attend.

Educational Objectives
After completing this activity, the participant should be able to:
  • Identify and evaluate dyslipidemia, lipodystrophy, and weight gain, as well as the presence of HIV-associated lipodystrophy in people living with HIV infection (PLWH).
  • Recognize the connected relationship of lipids, fat, and glucose and how this impacts weight gain.
  • Review the differences in management and treatment of dyslipidemia in people living with and without HIV infection.
  • Illustrate how to diagnose, manage and provide individualized treatment for patients with lipodystrophy.

Daniel Lee, MD, AAHIVS
Director of the Owen Lipid/Lipodystrophy Clinic​ at UCSD Medical Center

Disclosure of Conflicts of Interest

Daniel Lee, MD

  • Consultant with Thera technologies, ViiV Healthcare
  • Independent Contractor with ViiV Healthcare​​
  • Stock/Ownership in Gilead Sciences

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

In this activity the faculty do discuss the use of investigational antiretroviral agents and treatment regimens that are not approved by treatment guidelines.

This material is no longer available for CE. However, the slides are linked below for your review.

AL 2020 Workshop Lipids Lipodystrophy and Obesity Metabolic Issues in HIV